kadmy / iStockphoto.com
22 March 2018Americas
Novartis sues Regeneron over eye treatment
Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea (aflibercept) and Zaltrap (ziv-aflibercept).
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.
Americas
4 May 2021 Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.
Editor's picks
Editor's picks
Big Pharma
27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.
Americas
4 May 2021 Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.
Big Pharma
27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.
Americas
4 May 2021 Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.